Pharmaceutical companies are extensively dedicated to conduct research for the development of the solubility of limited aqueous soluble drug molecules and their bioavailability. Less soluble molecule can provide a number of challenges in pharmaceutical development such as slow dissolution in biological fluids, insufficient and inconsistent systemic exposure and consequent sub-optimal efficacy in patients via the oral route of administration [1]. Continuously an intensive research in the pharmaceutical sciences has documented several approaches to address the issues of low aqueous solubility and bioavailability.

References

1. Blagden N., et al. “Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates”. Advanced Drug Delivery Reviews 59 (2007): 617-630.
2. Desiraju GR. “Crystal Gazing: Structure Prediction and Polymorphism”. Science 278 (1997): 404-405.
3. Desiraju GR. “Crystal Engineering: The design of Organic Solids”. Elsevier, Amsterdam (1989).
4. Seddon KR and Zaworotko MJ. “Crystal Engineering: The Design and Application of Functional Solids”. NATO-ASI Series. Kluwer: Dordrecht, The Netherlands 539 (1999).
5. Black SN., et al. “Structure, solubility, screening and synthesis of molecular salts”. Journal of Pharmaceutical Sciences 96 (2007): 1053-1068.
6. Dai XL., et al. “Pharmaceutical cocrystallization: an effective approach to modulate the physicochemical properties of solid-state drugs”. CrystEngComm 20 (2018): 5292-5316.

Citation

Citation: Partha Pratim Bag. “Crystal Engineering for Pharmaceutical Solids". Acta Scientific Pharmaceutical Sciences 4.3(2020): 18.